arrow
C

Carl M. Gay

md anderson cancer center
H指数:38
被引数:8,220

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

新辅助度伐利尤单抗联合化疗在可切除或临界可切除非小细胞肺癌中的应用:MDT-BRIDGE II期临床试验

2026-10-260
OAAI
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

AZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测

2026-04-030
OAAI
The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer

靶向TRAF2和NCK相互作用蛋白激酶(TNIK)对c-MYC高表达小细胞肺癌的抗肿瘤效应及肿瘤免疫微环境的影响

2025-12-260
PRE
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer

多组学分析为小细胞肺癌的异质性、微环境特征和生物标志物景观提供了见解。

2025-12-020
OAAI
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
Multi-Site Profiling of Small Cell Lung Cancer and Assessment of Tumor Heterogeneity Through Rapid Research Autopsy

多中心小细胞肺癌分析及通过快速研究性尸检评估肿瘤异质性

2025-08-290
PRE
Reconstructing Small Cell Lung Cancer Evolution using Deep Whole Genome Sequencing of Circulating Tumor DNA

利用深度全基因组测序的循环肿瘤DNA重建小细胞肺癌进化

2025-08-290
PRE
Evaluating Therapeutic Marker Expression and EMT Heterogeneity in Circulating Tumor Cells from SCLC Liquid Biopsies using Mass Cytometry

评估小细胞肺癌液体活检循环肿瘤细胞中治疗性标志物表达和EMT异质性的方法学研究

2025-08-290
PRE
Combination Surface Targeting Strategies in Relapsed Small Cell Lung Cancer (SCLC) to Overcome Intratumoral Heterogeneity Associated with Treatment Resistance

在复发小细胞肺癌(SCLC)中结合表面靶向策略以克服与治疗耐药性相关的肿瘤内异质性

2025-08-290
PRE
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report

达拉他单抗在未经治疗的SCLC脑转移患者中快速颅内应答——真实世界病例系列:病例报告

2025-03-240
PRE
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

DNA损伤应答特征与广泛期小细胞肺癌的一线化疗反应及肿瘤进化途径相关。

2025-03-200
OA
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
2025-01-010
PRE
Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer (vol 10, 63, 2024)
2024-12-190
OAAI
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
2024-11-190
OAAI